HIV health care providers are ready to introduce pre-exposure prophylaxis in Central and Eastern Europe and neighbouring countries: data from the Euroguidelines in Central and Eastern Europe (ECEE) Network Group
Language English Country England, Great Britain Media print-electronic
Document type Journal Article, Multicenter Study
PubMed
29989332
DOI
10.1111/hiv.12641
Knihovny.cz E-resources
- Keywords
- EACS, HIV, Euroguidelines, central Europe, eastern Europe, pre-exposure prophylaxis,
- MeSH
- Safe Sex MeSH
- Adult MeSH
- Emtricitabine therapeutic use MeSH
- HIV Infections prevention & control MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Pre-Exposure Prophylaxis methods statistics & numerical data MeSH
- Surveys and Questionnaires MeSH
- Practice Guidelines as Topic MeSH
- Standard of Care MeSH
- Tenofovir therapeutic use MeSH
- Health Personnel MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
- Geographicals
- Europe MeSH
- Names of Substances
- Emtricitabine MeSH
- Tenofovir MeSH
OBJECTIVES: Pre-exposure prophylaxis (PrEP) for HIV infection has been introduced in only a few European countries. We investigated the potential to provide PrEP in the Central and Eastern European region, and in neighbouring countries. METHODS: The Euroguidelines in Central and Eastern Europe (ECEE) Network Group was formed in February 2016 to review standards of care for HIV infection in the region. Information related to PrEP was collected through on-line surveys. Respondents were recruited by ECEE members based on their involvement in HIV care. RESULTS: Seventy-six respondents from 23 countries participated in the survey. Twenty-six (34.2%) respondents reported that PrEP [tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC)] was registered by the drug registration authority in their country. Fifty-three (70.7%) respondents reported being aware of 'informal' PrEP use in their country. If they had access to PrEP, 56 (74.7%) would advise its use in their practice. Forty-five (59.2%) respondents had concerns regarding PrEP use, and 10 (13.3%) expressed the need for more training. Most of the respondents (88.2%) would provide PrEP to people with high-risk behaviours. CONCLUSIONS: PrEP is already used informally in some countries in the region. Physicians are keen to use PrEP if and when it is accessible. Obstacles towards implementing PrEP in those countries were mostly related to lack of national guidelines, drug registration and governmental strategy.
Clinic of the Gromahevsky Institute of Epidemiology and Infectious Diseases Kiev Ukraine
Department of Adults' Infectious Diseases Medical University of Warsaw Warsaw Poland
Department of Infectious and Tropical Diseases Hospital Na Bulovce Prague Czech Republic
Department of Infectious Diseases and Geographical Medicine University Hospital Bratislava Slovakia
Department of Infectious Diseases University Medical Center Ljubljana Ljubljana Slovenia
Hospital for Infectious Diseases HIV Out Patient Clinic Warsaw Poland
Hospital for Infectious Diseases Warsaw Poland
Infectious Diseases and Clinical Microbiology Ege University Medical Faculty Izmir Turkey
References provided by Crossref.org
HIV care in times of the COVID-19 crisis - Where are we now in Central and Eastern Europe?